AVRO earnings
AVROBIO Inc. (AVRO) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business UpdateProvided interim data at WORLDSymposium™ 2022 that showed sustained engraftment across first three patients 1+ year post-gene therapy in Phase 1/2 clinical triali for cystinosis; all remain off oral cysteamine to date Interim clinical data update of AVR-RD-02 in Gaucher disease type 1 planned for 2022; third patient dosed in Phase 1/2 clinical trial Regulatory interactions planned in 2022 to inform clinical development and registration strategies for programs in Gaucher disease, cystinosis, Hunter syndrome and Pompe disease Strong balance sheet with cash runway into Q1 2024 AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a li
- AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for CystinosisSustained engraftment observed across first three patients 1+ year post-gene therapy; all remain off oral cysteamine to date Reduction in number of cystine crystals as measured in skin and intestinal mucosa biopsies observed across first three patients Continued favorable safety profile with no adverse events related to drug product to date Clinical proof-of-concept in adult patients lays groundwork for AVROBIO-sponsored trial planned to begin in 2023 Analyst and investor conference call scheduled for today at 8:00 a.m. ET AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported
- AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022Analyst and investor conference call scheduled for Wednesday, Feb. 9, 2022, at 8:00 a.m. ET Five platform presentations and three posters on the company's clinical and preclinical programs for lysosomal disorders are scheduled throughout the symposium AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposium™ in San Diego, Calif. Additionally, preclinical data from its Pompe disease and Hunter syndrome programs, as we